Sinopharm subsidiary sees revenue, profit dip but cash flow improves

Sinopharm Group Co. Ltd.'s subsidiary, China National Medical Device Co., Ltd. (CNMDC), announced its unaudited financial data for the nine months ended September 30, 2025. During the period, CNMDC's revenue decreased by 2.41% to 54.69 billion yuan compared to the same period last year. Operating profit also saw a notable decline of 10.34%, reaching 962.11 million yuan. Total comprehensive income attributable to owners of the parent company fell by 2.71% to 395.28 million yuan.

Despite the declines in revenue and profit, CNMDC reported a substantial improvement in net cash flow from operating activities, which increased by 49.55%. The net cash outflow was 4.13 billion yuan, a considerable reduction from 8.18 billion yuan in the prior year's period.

As of September 30, 2025, total assets grew by 4.01% to 64.13 billion yuan compared to the beginning of the reporting period. Total equity attributable to owners of the parent company also increased by 3.86%, reaching 8.19 billion yuan.